Eurofins Scientific (ERF) EU Investor Day 2025 presentation summary

Strategic positioning and scale

• Operates over 950 laboratories in 60 countries, performing 450 million+ tests annually and employing 65,000+ people.

• Maintains a fully digital hub-and-spoke laboratory network, supporting scale and efficiency.

• Committed to sustainability, ESG, and ongoing innovation.

Financial performance and growth trajectory

• 2024 marked a return to pre-COVID profit and cash flow growth, with revenues of €6.95bn and adjusted EBITDA of €1.55bn.

• H1 2025 revenues grew 5.7% organically to €3.61bn, with adjusted EBITDA margin rising to 22.4%.

• Profit growth outpaced revenue due to margin expansion and cost discipline.

• Free cash flow to shareholders increased 150% year-on-year in 2024.

Market outlook and business mix

• Long-term organic growth target of 6.5% p.a., with biopharma, food, feed, and diagnostics as key drivers.

• Food & Feed Testing represents ~40% of revenue, biopharma ~30%, diagnostics ~20%, and consumer/technology ~10%.

• Growth supported by regulatory trends, innovation, and rising demand for safety and quality.